Johnson & Johnson Raises FY26 Outlook Following Positive Q2 Revenue
Johnson & Johnson (J&J) has reported a strong second quarter (Q2) in 2026, with revenues reaching around $25.3 billion, representing a year-over-year (YoY) increase of 6.6%. This positive performance has led to an upward revision of the company’s full-year 2026 (FY26) earnings guidance, with the new forecast now standing at $11.60-$11.75 per share.
Source: s.yimg.com
The company’s medtech division, J&J MedTech, accounted for more than a third of the total Q2 revenues, with a YoY uptick of 4.5%. J&J MedTech achieved revenues of around $8.93 billion in Q2, falling short of analysts’ average estimate of $8.97 billion. However, growth in this segment was driven by the company’s electrophysiology products and Shockwave intravascular lithotripsy (IVL) system in cardiovascular diseases.
J&J acquired Shockwave Medical in a $13.1 billion deal in June 2024, inheriting its IVL catheter for treating venous pathologies, including peripheral artery disease (PAD). The company’s IVL system was first launched in Europe in 2017, following the receipt of a CE mark in 2015. In 2016, Shockwave Medical became the first company to receive US Food and Drug Administration (FDA) approval for an IVL system for PAD treatment, with the first IVL catheter launched in the US in 2021.
Additionally, J&J MedTech’s contact lens performance in Q2 was driven by the company’s plans to strengthen its vision manufacturing provision in Florida, with a $1.1 billion investment announced recently. In contrast, the company’s pharma business reported growth primarily driven by core products, including Darzalex (daratumumab), Carvykti (ciltacabtagene autoleucel), Tecvayli (teclistamab-cqyv), and Rybrevant (amivantamab)/Lazcluze (lazertinib) in oncology, Tremfya (guselkumab) and others in immunology, and Spravato (esketamine) in neuroscience. The recent growth driver in neuroscience is Calypta (lumateperone), following J&J’s $14.6 billion acquisition of Intra-Cellular Therapies in April 2025.
Johnson & Johnson’s Chief Executive Officer, Joaquin Duato, expressed confidence in the company’s performance, stating, ‘With raised guidance and quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our Company’s 140-year history.’
Despite the positive Q2 results, J&J’s shares on the Nasdaq were down by around 1.5% at $250.09 at market open on July 15, 2026, compared to a prior close of $253.85. The company has a market capitalization of around $611 billion.
